Natus Medical Incorporated (BABY) Upgraded by Zacks Investment Research to “Buy”
Natus Medical Incorporated (NASDAQ:BABY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The firm presently has a $45.00 target price on the medical equipment provider’s stock. Zacks Investment Research‘s target price suggests a potential upside of 12.64% from the stock’s previous close.
According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “
Separately, BidaskClub raised Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Natus Medical has an average rating of “Hold” and an average price target of $46.50.
Shares of Natus Medical (NASDAQ:BABY) traded down 0.62% on Tuesday, reaching $39.95. The company had a trading volume of 444,969 shares. The company has a 50-day moving average price of $37.39 and a 200-day moving average price of $36.11. Natus Medical has a one year low of $31.65 and a one year high of $43.85. The firm has a market cap of $1.30 billion, a P/E ratio of 69.24 and a beta of 0.95.
Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.01. The company had revenue of $122.20 million during the quarter, compared to analysts’ expectations of $121.99 million. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The business’s revenue for the quarter was up 27.3% on a year-over-year basis. During the same period last year, the firm earned $0.39 EPS. On average, analysts expect that Natus Medical will post $1.70 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/24/natus-medical-incorporated-baby-upgraded-by-zacks-investment-research-to-buy.html.
In related news, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $35.17, for a total transaction of $154,748.00. Following the completion of the sale, the director now directly owns 50,850 shares of the company’s stock, valued at $1,788,394.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director William M. Moore sold 3,000 shares of Natus Medical stock in a transaction on Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the sale, the director now directly owns 30,410 shares of the company’s stock, valued at $1,036,981. The disclosure for this sale can be found here. 5.50% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in BABY. Benjamin F. Edwards & Company Inc. lifted its holdings in Natus Medical by 2,085.6% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock worth $102,000 after acquiring an additional 2,607 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in Natus Medical during the first quarter worth about $110,000. Riverhead Capital Management LLC lifted its holdings in Natus Medical by 90.9% during the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock worth $107,000 after acquiring an additional 1,364 shares in the last quarter. Sei Investments Co. lifted its holdings in Natus Medical by 29.7% during the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock worth $119,000 after acquiring an additional 728 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in Natus Medical by 94.0% during the first quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock worth $125,000 after acquiring an additional 1,543 shares in the last quarter. 94.57% of the stock is owned by institutional investors and hedge funds.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.